Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Malvatricin pharmaceutical forms for pharyngitis and oropharyngeal infection
ACTRN12614000114640Phase 4Recruiting
- Sponsor
- Laboratório Daudt
- Start
- Dec 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Malvatricin, oxyquinoline sulfate, tyrothricin, benzocaine and lidocaine in pharyngitis and oropharyngeal infection (6 arms), sponsored by Laboratório Daudt. Primary endpoint: Reduction of oropharyngeal microorganisms. Started Dec 2013; status: recruiting.
02
Drugs
Malvatricinoxyquinoline sulfatetyrothricinbenzocainelidocaine
03
Conditions
pharyngitisoropharyngeal infection
Beyond the preview
Go deeper on ACTRN12614000114640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000114640.